Secukinumab

Psoriatic arthritis with concomitant moderate to severe plaque psoriasis: follow the adult plaque psoriasis recommendation (300 mg at weeks 0, 1, 2, 3 and 4 then monthly; based on clinical response a maintenance dose of 300 mg every 2 weeks may provide additional benefit at body weight 90 kg or higher). Hidradenitis suppurativa: 300 mg at weeks 0, 1, 2, 3 and 4 then monthly, maintenance may be increased to 300 mg every 2 weeks. For all indications available data suggest clinical response is usually achieved within 16 weeks; consider discontinuing in patients with no response by 16 weeks, though some with an initial partial response may improve beyond 16 weeks. Elderly (65 years and over): no dose adjustment required. Juvenile idiopathic arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis, from 6 years) is dosed by weight band, not per kg: body weight under 50 kg 75 mg, 50 kg or above 150 mg, at weeks 0, 1, 2, 3 and 4 then monthly; the 150 mg and 300 mg pre-filled syringe and pre-filled pen are not indicated for paediatric patients weighing under 50 kg. Safety and efficacy below 6 years (plaque psoriasis, ERA, JPsA) and below 18 years in other indications have not been established. Verify all paediatric dosing against a children's formulary. SPC section 4.5 (interactions) was not retrieved in this bundle - the interaction listed below is from the US label section 7. Administration: avoid areas of skin showing psoriasis as injection sites; the syringe or pen must not be shaken; after proper training patients may self-inject or be injected by a caregiver if the physician determines this is appropriate.